Latest iteration of patent pending platform enables life
sciences and pharmaceutical companies to access insights from
billions of proprietary data points
LONDON, Aug. 9, 2023 /PRNewswire/ -- Clarivate Plc
(NYSE:CLVT), a global leader in connecting people and organizations
to intelligence they can trust to transform their world, today
launched its new enhanced search platform leveraging generative
artificial intelligence (GenAI). GenAI has the potential to yield
efficiencies across the entire Life Sciences & Healthcare value
chain. The new Clarivate offering enables drug discovery,
preclinical, clinical, regulatory affairs and portfolio strategy
teams to interact with multiple complex datasets using natural
language to obtain immediate and in-depth insights.
Rapid, accurate insights are challenged by a typical paradigm of
disparate, siloed data sources. Many standard databases and
companies have focused use cases and the ability to track
scientific innovation from start to finish is complex, costly, and
inefficient. The new Clarivate enhanced search platform addresses
these obstacles by pairing billions of proprietary data points and
over 100 years of deep industry and domain expertise with
GenAI capabilities. By integrating vast content sets and analytics
from solutions, including Cortellis Competitive Intelligence™,
Disease Landscape & Forecast™ and Drug Timelines and Success
Rates (DTSR) into the new interactive platform, users can
access harmonized data featuring precise, concise and immediate
answers to the life science industry's most urgent questions.
Researchers can access and interrogate epidemiologic,
scientific, clinical, commercial and research data within one
platform to overcome barriers to enabling evidence-based decisions
and complex analyses. Derived from advanced GenAI and data science
techniques that algorithmically process high-value curated content,
users can identify companies developing breakthrough therapies,
anticipate medical advancements and understand market dynamics,
essential for the advancement of bringing new therapies to market.
Additional features and functionalities include among others:
- Natural Language: Users can input questions using
natural language for an effortless search experience.
- Multi–faceted insights: Leverage proprietary Knowledge
Graph and non-relational databases combined with patent pending
traditional and GenAI data science methods to integrate systems and
unlock data connections.
- Intelligent Summarization: Users can access clear and
concise summarizations featuring the most relevant insights
leveraging its built-in knowledgebase of life sciences and
healthcare.
- Clear results: Data results are highlighted in dedicated
sections for ease of interpretation, analysis and review of
insights, avoiding hallucinations common to GenAI models.
- Continuous learning: Customers can benefit from adaptive
learning and constant improvement for consistently accurate
results. On-going user feedback, advancements in features and
algorithms, and the continuous integration of datasets will allow
for the delivery of new and unique insights.
The beta version of the enhanced search platform has been
launched with select customers to optimize the platform for use by
broader audiences by discovering new use cases, exploring UI
/ UX capabilities, obtaining and incorporating feedback and
previewing new features and functionality. Commercialization is
anticipated later this year, with plans to extend the knowledge
base by integrating additional datasets from solutions, including:
Cortellis Clinical Trials Intelligence™, Cortellis Deals
Intelligence™, OFF-X™ Safety Intelligence, Cortellis Drug Discovery
Intelligence™, Cortellis Regulatory Intelligence™ and others.
Clarivate will continue to evolve the platform with technical
enhancements, heightened search capabilities, data mapping and AI
model updates in the near term.
Henry Levy, President, Life
Sciences and Healthcare, Clarivate, said: "There is a growing
need for data to support complex analyses and evidence-based
decisions in the life sciences. As an early adopter of AI
technology, Clarivate utilizes billions of proprietary
best-in-class data assets to enable researchers to optimize
treatment development from early-stage drug discovery through
commercialization. The new Clarivate GenAI enhanced search platform
utilizes human expertise, billions of proprietary
best-in-class expertly curated and interconnected data assets, and
advanced AI models to enhance decision-making, advance research,
and boost clinical and commercial success across the entire drug,
device and medical technology lifecycle."
As a provider of best-in-class data integration/deidentified
patient solutions and a premier end-to-end research intelligence
solution, Clarivate is committed to comprehensively supporting
customers across the entire drug, device or diagnostic product
lifecycle to help them advance human health. Our continuing
investment in artificial intelligence (AI) and machine learning
(ML) supports the industry's ever-growing need to engage patients,
physicians and payers in new ways, navigate barriers to access and
adherence, and address patient unmet needs.
To learn more about the Clarivate enhanced search platform,
contact: LSHGenAI@clarivate.com.
About Clarivate
Clarivate™ is a leading global
information services provider. We connect people and organizations
to intelligence they can trust to transform their perspective,
their work and our world. Our subscription and technology-based
solutions are coupled with deep domain expertise and cover the
areas of Academia & Government, Life Sciences & Healthcare
and Intellectual Property. For more information, please visit
www.clarivate.com.
Media contact:
Catherine Daniel
Director External Communications, Life Sciences &
Healthcare
newsroom@clarivate.com
Logo -
https://mma.prnewswire.com/media/1159266/Clarivate_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/clarivate-launches-enhanced-search-powered-by-generative-artificial-intelligence-301896298.html